NYSE · Biotechnology

Alto Neuroscience, Inc. (ANRO) Stock

$24.37 +1.41% NYSE: ANRO Healthcare

Valuation

MetricValue
Price$24.37
Market Cap$855.24M
P/E Ratio-9.71
P/B Ratio4.70
P/S Ratio0.00
EPS (TTM)$0.00
52-Week High$37.48
52-Week Low$5.22
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-46.46%
ROA-33.16%
ROCE18.72%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity0.03
Current Ratio16.18

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$0$0$0$0
Operating Profit$-12.0M$-29.0M$-38.0M$-69.0M$-66.0M
Net Profit$-9.0M$-28.0M$-36.0M$-61.0M$-63.0M
EPS$-0.36$-1.08$-1.35$-2.50$-2.19
Op Margin-5740.9%————

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$29.0M$51.0M$87.0M$178.0M$185.0M
Total Liabilities$41.0M$89.0M$158.0M$26.0M$34.0M
Cash$26.0M$48.0M$83.0M$168.0M$176.0M
Borrowings$38.0M$82.0M$10.0M$17.0M$4.0M

Latest News

Alto Neuroscience Prices $100 Million Stock Offering MT Newswires · Jul 13, 2026 Alto Neuroscience Announces Pricing of $100.0 Million Underwritten Registered Direct Offering of Common Stock Business Wire · Jul 13, 2026 Is Alto Neuroscience, Inc. (ANRO) Stock Positioned for Growth With New Insights Into Anhedonia Treatment? Insider Monkey · Jul 2, 2026 Alto Neuroscience Highlights Nature Medicine Publication Demonstrating Significant Effects of Pramipexole on Anhedonia Business Wire · Jun 15, 2026 Alpha Wave Global Initiates COPT Defense Properties Position, According to Recent SEC Filing Motley Fool · May 27, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-9.0M$-20.0M$-33.0M$-47.0M$-52.0M
Investing Cash Flow$-1.0M$-1.0M$-1.0M$-4.0M$0
Financing Cash Flow$0$0$-2.0M$-3.0M$0
Net Cash Flow$22.0M$23.0M$34.0M$86.0M$8.0M
Free Cash Flow$-10.0M$-21.0M$-34.0M$-49.0M$-52.0M

Valuation & Return Ratios

MetricValue
PEG Ratio1.96
EV / EBITDA-7.47
FCF Yield-8.14%
Quick Ratio14.85
Interest Coverage19.66
Return 1Y774.59%
Return 3Y—
Return 5Y—

Ownership

Insiders Held4.11%
Institutions Held74.13%
Institutions Float Held77.32%
Institutional HolderSharesReport Date
Alpha Wave Global, LP3,707,7572026-03-31
Commodore Capital Lp2,723,1962026-03-31
Vestal Point Capital, LP2,064,0752026-03-31
Perceptive Advisors Llc2,009,8932026-03-31
Spruce Street Capital LP1,325,2102026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ACIUAC Immune SA $2.50 -1.96% -5.24 $254.43M 0.00%
ALDXAldeyra Therapeutics, Inc. $0.92 -3.31% -3.02 $55.27M 0.00%
AMRNAmarin Corporation plc $14.58 +0.80% -9.00 $301.45M 0.00%
CLLSCellectis S.A. $2.81 -2.26% -4.14 $282.17M 0.00%
CTNMContineum Therapeutics, Inc. $13.38 +1.52% -7.58 $503.37M 0.00%

About Alto Neuroscience, Inc.

Alto Neuroscience, Inc. is led by CEO Amit Etkin, employs 76 people, headquartered in US, publicly traded since 2024.

Alto Neuroscience, Inc. (ANRO) stock trades at $24.37 with a market capitalization of $855.24M. The stock is valued at a price-to-earnings (P/E) ratio of -9.71, price-to-book of 4.70, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $5.22 and $37.48, and currently trades 35.0% below its 52-week high.

On profitability, Alto Neuroscience, Inc. generates a return on equity (ROE) of -46.46%, return on capital employed of 18.72%, an operating margin of 0.00%, a net profit margin of 0.00%.

Related Healthcare Stocks

LLY Eli Lilly and Company $1179.27 +0.83% JNJ Johnson & Johnson $261.44 +1.93% ABBV AbbVie Inc. $276.47 +1.49% MRK Merck & Company, Inc. Common Stock (new) $145.60 +2.26% UNH UnitedHealth Group Incorporated Common Stock (DE) $379.30 +2.25% NVS Novartis AG $143.75 +0.45% AZN AstraZeneca PLC $159.20 +0.26% TMO Thermo Fisher Scientific Inc $658.02 +0.93% AMGN Amgen Inc. $414.87 +1.82% GILD Gilead Sciences, Inc. $151.17 +2.77% ABT Abbott Laboratories $99.60 +1.13% NVO Novo Nordisk A/S $38.64 +1.20%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNYSE High ROE StocksAll stock screens
Run Stock Screener Investing Guides